生殖系ALK变异与胶质瘤及IDH野生型胶质母细胞瘤不良预后相关
该研究对99例胶质瘤患者行全外显子测序,探索生殖系变异与预后关系。12/99(12.12%)检出gALK-Mut,其在全部胶质瘤组和IDH野生型胶质母细胞瘤(39例)中总生存均显著短于gALK-WT(P=0.013和0.027)。结论认为ALK变异是胶质瘤和IDH-WT-GBM不良预后的独立指标,可能成为生物标志物和治疗靶点。
要点
- 全部胶质瘤病例均携带罕见生殖系变异,gALK-Mut占12/99(12.12%)。
- gALK-Mut在全部胶质瘤组和IDH-WT-GBM组中总生存均显著缩短(P=0.013和0.027)。
- IDH-WT-GBM中gALK-Mut者BIRC5、PIK3CA、RPN1体细胞突变频率更高。
核心结论
- 生殖系ALK变异是胶质瘤和IDH野生型胶质母细胞瘤不良预后的独立指标,可能成为有前景的生物标志物和可干预治疗靶点。
研究设计与样本
- 对99例胶质瘤病例行全外显子测序以探索生殖系变异,并分析其与临床病理特征及其他预后指标的关系。
主要发现
- 12/99(12.12%)患者检出gALK-Mut;gALK-Mut在全部胶质瘤组(99例)和IDH-WT-GBM亚组(39例)中总生存均显著短于gALK-WT(P=0.013和0.027)。
- IDH-WT-GBM中gALK-Mut患者BIRC5、PIK3CA和RPN1体细胞突变频率高于gALK-WT患者。
- IDH-WT-GBM中gALK-Mut/TP53-Mut亚组预后差于gALK-WT/TP53-Mut亚组(P=0.031)。
- gALK-Mut/TERT-WT和gALK-Mut/TERT-Mut亚组预后均差于gALK-WT/TERT-Mut亚组(P=0.031和0.018)。
临床怎么用
- 对胶质瘤尤其IDH-WT-GBM患者,可关注生殖系ALK变异作为预后分层参考,并结合TP53、TERT状态综合评估。
局限性
- 原文提及其他混杂因素似乎也影响患者生存,样本量有限(99例,IDH-WT-GBM仅39例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioma is the most common primary brain tumor. Clear classification is crucial for accurate diagnosis and individualized treatment. Histopathological characteristics and genetic alterations have shown to be related to prognosis and treatment response. Germline variants are important components of genetic alterations. However, the distribution of germline variations in glioma patients and their association with survival remain unknown. METHODS: We carried out whole-exome sequencing on 99 cases to explore germline variants in glioma. We also analyzed the association of germline variants with clinicopathological features and other prognostic indicators. RESULTS: All the glioma cases harbored rare germline variants. Germline ALK variants (gALK-Mut) were identified in 12/99 (12.12%) patients. The gALK-Mut patients had significantly shorter overall survival than germline ALK wildtype (gALK-WT) patients in the all glioma group (99 cases) and the subset of patients with IDH-wildtype glioblastoma (IDH-WT-GBM, 39 cases) (P = 0.013 and 0.027, respectively). The gALK-Mut patients also had higher frequency of BIRC5, PIK3CA and RPN1 somatic mutations than the gALK-WT patients in IDH-WT-GBM. Other confounding factors appeared to contribute to patient survival. The subgroup of patients in IDH-WT-GBM with gALK-Mut/TP53-Mut had worse prognosis than the gALK-WT/TP53-Mut subgroup (P = 0.031); The gALK-Mut/TERT-WT and gALK-Mut/TERT-Mut subgroups both had a worse prognosis than the gALK-WT/TERT-Mut subgroup (P = 0.031 and 0.018, respectively). CONCLUSIONS: Our study revealed ALK variation was an independent indicator of poor prognosis in glioma and IDH-WT-GBM. It could be a promising biomarker and tractable therapeutic target for this deadly disease.
引用
- Bu L, Hameed NUF, Luo C, et al. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma. J Neurooncol. 2021. PMID: 33486679. doi:10.1007/s11060-020-03676-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。